317 related articles for article (PubMed ID: 17269700)
41. Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1.
Pan LQ; Xie ZM; Tang XJ; Wu M; Wang FR; Naranmandura H; Chen SQ
Appl Microbiol Biotechnol; 2013 Aug; 97(16):7253-64. PubMed ID: 23208613
[TBL] [Abstract][Full Text] [Related]
42. Functional solubilization of aggregation-prone TRAIL protein facilitated by coexpressing with protein isoaspartate methyltranferase.
Zhu H; Pan RJ; Wang TW; Shen YL; Wei DZ
Appl Microbiol Biotechnol; 2006 Oct; 72(5):1033-8. PubMed ID: 16575568
[TBL] [Abstract][Full Text] [Related]
43. Bacterial fermentation of recombinant major wasp allergen Antigen 5 using oxygen limiting growth conditions improves yield and quality of inclusion bodies.
Kischnick S; Weber B; Verdino P; Keller W; Sanders EA; Anspach FB; Fiebig H; Cromwell O; Suck R
Protein Expr Purif; 2006 Jun; 47(2):621-8. PubMed ID: 16495080
[TBL] [Abstract][Full Text] [Related]
44. GroEL/ES mediated the in vivo recovery of TRAIL inclusion bodies in Escherichia coli.
Wang Z; Zhang M; Lv X; Fan J; Zhang J; Sun J; Shen Y
Sci Rep; 2018 Oct; 8(1):15766. PubMed ID: 30361617
[TBL] [Abstract][Full Text] [Related]
45. Fusion tags and chaperone co-expression modulate both the solubility and the inclusion body features of the recombinant CLIPB14 serine protease.
Schrödel A; Volz J; de Marco A
J Biotechnol; 2005 Oct; 120(1):2-10. PubMed ID: 16023240
[TBL] [Abstract][Full Text] [Related]
46. Efficient solubilization of inclusion bodies.
Freydell EJ; Ottens M; Eppink M; van Dedem G; van der Wielen L
Biotechnol J; 2007 Jun; 2(6):678-84. PubMed ID: 17492713
[TBL] [Abstract][Full Text] [Related]
47. Solubilization and refolding of bacterial inclusion body proteins.
Singh SM; Panda AK
J Biosci Bioeng; 2005 Apr; 99(4):303-10. PubMed ID: 16233795
[TBL] [Abstract][Full Text] [Related]
48. Refolding and purification of the human secreted group IID phospholipase A2 expressed as inclusion bodies in Escherichia coli.
Fonseca RG; Ferreira TL; Ward RJ
Protein Expr Purif; 2009 Oct; 67(2):82-7. PubMed ID: 19376232
[TBL] [Abstract][Full Text] [Related]
49. Matrix-assisted refolding of oligomeric small heat-shock protein Hsp26.
Franzmann TM
Int J Biol Macromol; 2006 Aug; 39(1-3):104-10. PubMed ID: 16626802
[TBL] [Abstract][Full Text] [Related]
50. Solubilization of Escherichia coli recombinant proteins from inclusion bodies.
Simpson RJ
Cold Spring Harb Protoc; 2010 Sep; 2010(9):pdb.prot5485. PubMed ID: 20810632
[TBL] [Abstract][Full Text] [Related]
51. A simplified method for the efficient purification and refolding of recombinant human TRAIL.
Zhang Z; Hahn SB; Cao TM; King MR
Biotechnol Prog; 2020 Sep; 36(5):e3007. PubMed ID: 32329219
[TBL] [Abstract][Full Text] [Related]
52. Adsorptive refolding of a highly disulfide-bonded inclusion body protein using anion-exchange chromatography.
Chen Y; Leong SS
J Chromatogr A; 2009 Jun; 1216(24):4877-86. PubMed ID: 19419725
[TBL] [Abstract][Full Text] [Related]
53. Over-expression of recombinant human phospholipid scramblase 1 in E. coli and its purification from inclusion bodies.
Sahu SK; Gopala Krishna A; Gummadi SN
Biotechnol Lett; 2008 Dec; 30(12):2131-7. PubMed ID: 18629440
[TBL] [Abstract][Full Text] [Related]
54. Refolding and purification of rhNTA protein by chromatography.
Fan X; Xu D; Lu B; Xia J; Wei D
Biomed Chromatogr; 2009 Mar; 23(3):257-66. PubMed ID: 19101913
[TBL] [Abstract][Full Text] [Related]
55. Refolding and reconstitution of human recombinant Bax inhibitor-1 into liposomes from inclusion bodies expressed in Escherichia coli.
Ahn T; Yun CH; Chae HZ; Kim HR; Chae HJ
Protein Expr Purif; 2009 Jul; 66(1):35-8. PubMed ID: 19284981
[TBL] [Abstract][Full Text] [Related]
56. On-column refolding of recombinant human interleukin-4 from inclusion bodies.
Razeghifard MR
Protein Expr Purif; 2004 Sep; 37(1):180-6. PubMed ID: 15294296
[TBL] [Abstract][Full Text] [Related]
57. A screening system for the identification of refolding conditions for a model protein kinase, p38alpha.
Cowan RH; Davies RA; Pinheiro TT
Anal Biochem; 2008 May; 376(1):25-38. PubMed ID: 18294951
[TBL] [Abstract][Full Text] [Related]
58. Impact of different cultivation and induction regimes on the structure of cytosolic inclusion bodies of TEM1-beta-lactamase.
Margreiter G; Schwanninger M; Bayer K; Obinger C
Biotechnol J; 2008 Oct; 3(9-10):1245-55. PubMed ID: 18702088
[TBL] [Abstract][Full Text] [Related]
59. [Application of a prediction model in inclusion body refolding].
Zhang T; Wang JF; Feng YY; Yang Z; Ma L; Wang XN
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2156-60. PubMed ID: 19923054
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
